Next Article in Journal
Treatment-Free Remission in Chronic Myeloid Leukemia: Lights and Shadows
Previous Article in Journal
How I Treat Relapsed and/or Refractory Multiple Myeloma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 12
Issue s1
10.4081/hr.2020.8951
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Conference Report

How We Manage Smoldering Multiple Myeloma

by
Alessandra Romano
1,*,
Claudio Cerchione
2,*,
Concetta Conticello
3,
Giovanni Martinelli
2 and
Francesco Di Raimondo
1,3
1
Dipartimento di Chirurgia e Specialità Medico-Chirurgiche, Sezione di Ematologia, Università degli Studi di Catania, 95121 Catania, Italy
2
Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014 Meldola, Italy
3
U.O.C. di Ematologia, Azienda Policlinico Rodolico San Marco, 95121 Catania, Italy
*
Authors to whom correspondence should be addressed.
Hematol. Rep. 2020, 12(s1), 8951; https://doi.org/10.4081/hr.2020.8951
Submission received: 21 September 2020 / Revised: 21 September 2020 / Accepted: 21 September 2020 / Published: 21 September 2020

Abstract

Smoldering myeloma (SMM) is an asymptomatic stage characterized by bone marrow plasma cells infiltration between 10–60% in absence of myeloma-defining events and organ damage. Until the revision of criteria of MM to require treatment, two main prognostic models, not overlapping each other, were proposed and used differently in Europe and in US. Novel manageable drugs, like lenalidomide and monoclonal antibodies, with high efficacy and limited toxicity, improvement in imaging and prognostication, challenge physicians to offer early treatment to high-risk SMM. Taking advantage from the debates offered by SOHO Italy, in this review we will update the evidence and consequent clinical practices in US and Europe to offer readers a uniform view of clinical approach at diagnosis, follow-up and supportive care in the SMM setting.
Keywords: smoldering multiple myeloma smoldering multiple myeloma

Share and Cite

MDPI and ACS Style

Romano, A.; Cerchione, C.; Conticello, C.; Martinelli, G.; Di Raimondo, F. How We Manage Smoldering Multiple Myeloma. Hematol. Rep. 2020, 12, 8951. https://doi.org/10.4081/hr.2020.8951

AMA Style

Romano A, Cerchione C, Conticello C, Martinelli G, Di Raimondo F. How We Manage Smoldering Multiple Myeloma. Hematology Reports. 2020; 12(s1):8951. https://doi.org/10.4081/hr.2020.8951

Chicago/Turabian Style

Romano, Alessandra, Claudio Cerchione, Concetta Conticello, Giovanni Martinelli, and Francesco Di Raimondo. 2020. "How We Manage Smoldering Multiple Myeloma" Hematology Reports 12, no. s1: 8951. https://doi.org/10.4081/hr.2020.8951

APA Style

Romano, A., Cerchione, C., Conticello, C., Martinelli, G., & Di Raimondo, F. (2020). How We Manage Smoldering Multiple Myeloma. Hematology Reports, 12(s1), 8951. https://doi.org/10.4081/hr.2020.8951

Article Metrics

Back to TopTop